A Multicenter, Randomized Controlled Trial of the Efficacy, Safety and Immunogenicity of HPV Vaccination in Preventing Recurrence of HSIL in HIV-positive MSM
Latest Information Update: 15 Jun 2022
At a glance
- Drugs V 503 (Primary)
- Indications Anal dysplasia; Anal intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms HPV-SAVE
Most Recent Events
- 09 Jun 2022 Planned number of patients changed from 206 to 228.
- 09 Jun 2022 Planned End Date changed from 1 May 2020 to 1 May 2026.
- 09 Jun 2022 Planned primary completion date changed from 1 May 2020 to 1 Mar 2026.